Aurinia Pharmaceuticals (FRA:IKAP) Minority Interest: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IKAP Aurinia Pharmaceuticals Inc FRA:IKAP
79 GF Score
Price €12.83
GF Value €12.17
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals Minority Interest?

Aurinia Pharmaceuticals FRA:IKAP -0.85% 79 Minority Interest is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:IKAP with a GF Score™ of 79/100 and a GF Value™ of €12.17 (Fairly Valued). The stock has 3 warning signs investors should review.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Aurinia Pharmaceuticals's minority interest for the quarter that ended in Mar. 2026 was €0.00 Mil.

Aurinia Pharmaceuticals Minority Interest Historical Data

* Premium members only.

The historical data trend for Aurinia Pharmaceuticals's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals Minority Interest Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Minority Interest
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aurinia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:IKAP
79GF Score
Aurinia Pharmaceuticals Inc FRA:IKAP
Minority Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurinia Pharmaceuticals Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of €0.00 Mil mean?
Aurinia Pharmaceuticals (FRA:IKAP) has a Minority Interest of €0.00 Mil as of Mar. 2026. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Aurinia Pharmaceuticals.
Is Aurinia Pharmaceuticals' Minority Interest too high?
Aurinia Pharmaceuticals' current Minority Interest is €0.00 Mil. Overall, Aurinia Pharmaceuticals has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Minority Interest compare to PVLA and URGN?
Aurinia Pharmaceuticals' Minority Interest of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Aurinia Pharmaceuticals. Aurinia Pharmaceuticals's current Minority Interest is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (FRA:IKAP) is currently considered Fairly Valued. The stock's GF Value™ is €12.17, compared to a current price of €12.83 — trading 5.4% above its estimated fair value. The current Minority Interest is €0.00 Mil. Aurinia Pharmaceuticals' overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Aurinia Pharmaceuticals (FRA:IKAP), the current Minority Interest is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurinia Pharmaceuticals (FRA:IKAP) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of €12.83 is trading 5.4% above its estimated GF Value™ of €12.17. GuruFocus considers Aurinia Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:IKAP:

  • Minority Interest: €0.00 Mil
  • GF Value™: €12.17 vs. price of €12.83 (5.4% above fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the FRA:IKAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurinia Pharmaceuticals Business Description

Other Exchanges AUPH:USAIKAP:Germany
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
79GF Score

Get the complete analysis for FRA:IKAP

Minority Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.83
Price
€12.17
GF Value